China: How to keep up and win in the world's fastest changing healthcare market
China's population will start to shrink in 2023 placing greater weight on the working population who have to support increasing numbers of 65+ year olds. The aging population combined with a surge in non-communicable diseases has led to a higher disease burden and more pressure on an already overstretched healthcare system. Seeking to modernise, China has undertaken a range of reforms.
Webcast: China in the Fast Lane - How to play and win in the world's hottest emerging market
Watch this webcast in which Pei Li Teh and Wan Ling Neo explore China's evolving healthcare environment. In this webcast they highlight the key changes affecting pharma and demonstrate how to build the market understanding required to launch a brand effectively in this exciting region.
Fast and furious: What will the fast tracking of approvals for key drugs mean for China's pharma market?
China has long been a magnet for pharmaceutical multinationals looking to offset flattening growth in established markets
It offers rapid economic development, a population of around 1.4 billion with limited access to cutting-edge medicine, and changing lifestyles that have raised health expectations. Expanded access to state-funded healthcare, population aging and a growing burden of chronic disease are creating new opportunities for innovative drugs alongside low-cost generics.
China in the fast lane: Access opportunities for novel therapies in the world's hottest emerging market
In our latest article for pharmaphorum's Deep Dive magazine, Brett Gardiner and Boon Yap discuss access opportunities for novel therapies in the world’s hottest emerging market.
The sheer size of China’s population (1.4 billion) has long made it an attractive market for pharma in terms of potential volume, especially in the context of rising affluence associated with a growing middle class. In 2017, China was ranked the second largest pharmaceutical market in the world, behind the US. However, it has traditionally been a challenging market to launch into, particularly for manufacturers developing innovative and novel therapies. Recent changes to China’s regulations under its 2025 Made in China strategic plan – including an expedited market access process, more frequent updates to Reimbursed Drugs Listings and additional routes to reimbursement – look set to transform this paradigm and necessitate a reconsideration of manufacturers’ strategies to obtaining optimal pricing and reimbursement (P&R).
China in the Fast Lane: How to play and win in the world's hottest emerging market
Watch this webcast where Marc Yates and Helen Ansell explore China's evolving healthcare environment. The webcast highlights the key changes affecting pharma and demonstrates how to build the market understanding required to launch a brand effectiviely in this exciting region.